Project Grant HT94252411020
Award Date
9/15/24
Completion Date
9/14/26
Dollars Obligated
$473K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
This federal Project Grant award for $708,750.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a next-generation, off-the-shelf CAR-NKT cell therapy for the treatment of metastatic clear cell renal cell carcinoma. The award was granted to the University of California, Los Angeles (UCLA) on September 15, 2024, with a project period ending on September 14, 2026. This research aims to advance...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $630,000.00 to the University of California, Los Angeles (UCLA) for intravesical nectin4 chimeric antigen receptor T cell therapy research for non-muscle invasive bladder cancer. The award period runs from September 1, 2024 to August 31, 2026. As the prime awardee, UCLA will leverage its facilities, faculty expertise, and administrative capabilities...
The Regents of the University of California, San Francisco was awarded a $2,018,750 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from August 1, 2022 to July 31, 2025 to develop nano-CARS technology for the treatment of MLLR B-cell acute lymphoblastic leukemia. The Military Medical Research and Development program aims to transform military and public health...
The University of California, Los Angeles (UCLA) was awarded a $1,559,999 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund the development of an off-the-shelf car-inkt cell therapy for the treatment of multiple myeloma. The therapy will be developed and tested at UCLA's Office of Research Administration facilities in Los Angeles, California over a three-year period concluding September...
The Department of the Army Medical Command awarded a $188,403 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Los Angeles (UCLA) for the project "DEVELOPING NEW CELL-MEDIATED IMMUNOTHERAPEUTIC STRATEGIES FOR SMALL-CELL LUNG CANCER". The award, which runs from January 1, 2025 to December 31, 2025, supports advanced biomedical research focused on transforming healthcare for military service members and the broader...
The University of California, Los Angeles (UCLA) was awarded a $961,089 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research targeting mitochondrial defects in kidney cancer from September 1, 2022 to August 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
The Department of the Army Medical Command awarded a $1,339,689 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Feinstein Institutes for Medical Research. The purpose of this 4-year award, effective August 1, 2024, is to identify and functionally characterize metastasis-driving tumor cell subpopulations in localized stage III clear cell renal cell carcinoma. This research aims to transform healthcare for military service members and the broader...
The University of California, Los Angeles (UCLA) was awarded a $662,086 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from May 1, 2022 to April 30, 2025 to investigate NUDT5 as a novel target for ovarian cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goal of transforming health care for...
The University of California, Los Angeles (UCLA) was awarded a $1.56 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) for the period of June 30, 2022 to June 29, 2025. The grant will support research to exploit DNA repair defects in renal cell carcinoma that is deficient in Krebs cycle enzymes. Specifically, the university will identify efficacious combinations of DNA damage response inhibitors in...